Intravenous golimumab in rheumatoid arthritis

被引：9

作者：

Cohen, Marc D. ^{[1
]}

Keystone, Edward C. ^{[2
,3
]}

机构：

[1] Mayo Clin, Denver, CO 80218 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Mt Sinai Hosp, Toronto, ON M5T 3L9, Canada

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2014年 / 10卷 / 07期

关键词：

anti-TNF-; antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF- inhibition; TNF-; inhibition; ALPHA MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; PHASE-III; ANKYLOSING-SPONDYLITIS; METHOTREXATE THERAPY; SAFETY; EFFICACY; PHARMACOKINETICS;

D O I：

10.1586/1744666X.2014.918847

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.

引用

页码：823 / 830

页数：8

共 50 条

[21] Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Rossini, M.
Viapiana, O.
Orsolini, G.
Fracassi, E.
Idolazzi, L.
Gatti, D.
Adami, S.
Govoni, M.
REUMATISMO, 2014, 66 (04) : 285 - 303
[22] Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis
Shono E.
Drugs in R&D, 2013, 13 (1) : 95 - 100
[23] Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis
Tanaka, Yoshiya
Senoo, Asako
Fujii, Hideji
Baker, Daniel
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 319 - 326
[24] COMPREHENSIVE DISEASE CONTROL WITH GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
Combe, B.
Veale, D.
Burgos-Vargas, R.
Szucs, G.
Leirisalo-Repo, M.
Yao, R.
Govoni, M.
Vastesaeger, N.
Weng, H. H.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 223 - 224
[25] Inhibition of JNK in synovium by treatment with golimumab in rheumatoid arthritis
Kanbe, Katsuaki
Chiba, Junji
Nakamura, Atsushi
RHEUMATOLOGY INTERNATIONAL, 2014, 34 (01) : 125 - 130
[26] Antisynthetase Syndrome Triggered by Golimumab Treatment for Rheumatoid Arthritis
Jilkine, Konstantin
Haig, Sara
JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 888 - 888
[27] SAFETY AND EFFICACY OF BIOLOGICS IN ELDERIY PATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL WORLD STUDY: USE OF INTRAVENOUS GOLIMUMAB AND INFLIXIMAB IN ADULTS WITH RHEUMATOID ARTHRITIS '65 YEARS OF ACE
Zazzetti, Federico
Schechtman, Joy
Broadwell, Aaron
Kafka, Shelly
Black, Shawn
Xu, Stephen
Langholff, Wayne
Schwartzman, Sergio
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S109 - S110
[28] SAFETY AND EFFICACY OF BIOLOGICS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL WORLD STUDY: USE OF INTRAVENOUS GOLIMUMAB AND INFLIXIMAB IN ADULTS WITH RHEUMATOID ARTHRITIS ≥65 YEARS OF AGE
Schechtman, J.
Broadwell, A.
Kafka, S.
Black, S.
Xu, S.
Langholff, W.
Schwartzman, S.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 527 - 528
[29] Comparison of Baseline Characteristics of Rheumatoid Arthritis Patients Initiating Therapy with Subcutaneous Golimumab and Infliximab and Intravenous Golimumab: An Analysis from the Prospective, Observational Registry, BioTRAC
Faraawi, Rafat
Olszynski, Wojciech
Chow, Andrew
Baker, Milton
Haraoui, Boulos
Karellis, Angeliki
Psaradellis, Eliofotisti
Nantel, Francois
Lehman, Allen
Tkaczyk, Cathy
Maslova, Karina
Osborne, Brendan
JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1186 - 1186
[30] Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Tesser, John
Lin, Iris
Shiff, Natalie J.
Chakravarty, Soumya D.
Schmajuk, Gabriela
Hammam, Nevin
Desai, Sheetal
CLINICAL RHEUMATOLOGY, 2022, 41 (08) : 2319 - 2327

← 1 2 3 4 5 →